Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2960-2964

  Dodds Ashley, Elizabeth S ^a   Varkey, Jay B ^a   Krishna, Gopal ^b   Vickery, Donna ^b   Ma, Lei ^b   Yu, Xin ^b   Malavade, Darshana ^b   Goodwin, Megan ^a   Perfect, John R ^a   Power, Eddie ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NASOGASTRIC TUBE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; FEMALE; HUMANS; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; TRIAZOLES; YOUNG ADULT;

EID: 67649975620     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01178-08     Document Type: Article

References (25)

1. Buijk, S. L. C. E., I. C. Gyssens, J. W. Mouton, H. A. Verbrugh, D. J. Touw, and H. A. Bruining. 2001. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med. 27:115-121.
2. Cornely, O. A., J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann, T. J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y.-T. Goh, M. Petrini, C. Hardalo, R. Suresh, and D. Angulo-Gonzalez. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
3. Courtney, R., S. Pai, M. Laughlin, J. Lim, and V. Batra. 2003. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47: 2788-2795.
4. Courtney, R., D. Wexler, E. Radwanski, J. Lim, and M. Laughlin. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222.
5. Davies, A. R. 2007. Practicalities of nutrition support in the intensive care unit. Curr. Opin. Clin. Nutr. Metab. Care 10:284-290.
6. Ezzet, F., D. Wexler, R. Courtney, G. Krishna, J. Lim, and M. Laughlin. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220.
7. Grau, S., A. J. Mateu-De, F. Alvarez-Lerma, M. Marin-Casino, and J. M. Torres-Rodriguez. 2006. Successful treatment of an Aspergillus fumigatus infection with voriconazole via a nasogastric tube. J. Chemother. 18:445-446.
8. Greenberg, R. N., K. Mullane, J.-A. H. van Burik, I. Raad, M. J. Abzug, G. Anstead, R. Herbrecht, A. Langston, K. A. Marr, G. Schiller, M. Schuster, J. R. Wingard, C. E. Gonzalez, S. G. Revankar, G. Corcoran, R. J. Kryscio, and R. Hare. 2006. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50:126-133.
9. Keating, G. M. 2005. Posaconazole. Drugs 65:1553-1567.
10. Krishna, G., M. Martinho, P. Chandrasekar, A. J. Ullmann, and H. Patino. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636.
11. Krishna, G., A. Moton, L. Ma, M. M. Medlock, and J. McLeod. 2009. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966.
12. Martinez, V., J.-L. Le Guillou, C. Lamer, M. Le Jouan, M. Tod, and F. Dromer. 2003. Serum voriconazole levels following administration via percutaneous jejunostomy tube. Antimicrob. Agents Chemother. 47:3375.
13. Mohammedi, I., M. A. Piens, C. Padoin, and D. Robert. 2005. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 24:358-360.
14. Nicolau, D. P., H. Crowe, C. H. Nightingale, and R. Quintiliani. 1995. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J. Antimicrob. Chemother. 36:395-401.
15. Ong, D. L., and L. M. Fobes. 1996. Administering itraconazole via nasogastric tube. Am. J. Health Syst. Pharm. 53:1962.
16. Pille, S., and D. Bohmer. 1998. Options for artificial nutrition of cancer patients. Strahlenther. Onkol. 174:52-55.
17. Raad, I. I., J. R. Graybill, A. B. Bustamante, O. A. Cornely, V. Gaona-flores, C. Afif, D. R. Graham, R. N. Greenberg, S. Hadley, A. Langston, R. Negroni, J. R. Perfect, P. Pitisuttithum, A. Restrepo, G. Schiller, L. Pedicone, and A. J. Ullmann. 2006. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. 42:1726-1734.
18. Raad, I. I., R. Y. Hachem, R. Herbrecht, J. R. Graybill, R. Hare, G. Corcoran, and D. P. Kontoyiannis. 2006. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42:1398-1403.
19. Rosemurgy, A. S., S. Markowsky, S. E. Goode, K. Plastino, and R. E. Kearney. 1995. Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration. J. Trauma 39:445-447.
20. Sansone-Parsons, A., G. Krishna, A. Calzetta, D. Wexler, B. Kantesaria, M. A. Rosenberg, and M. A. Saltzman. 2006. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50:1881-1883.
21. Sansone-Parsons, A., G. Krishna, J. Simon, P. Soni, B. Kantesaria, J. Herron, and R. Stoltz. 2007. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 51:495-502.
22. Shen, J. X., G. Krishna, and R. N. Hayes. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 43:228-236.
23. Ullmann, A. J., J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston, S. R. Tarantolo, H. Greinix, W. Morais de Azevedo, V. Reddy, N. Boparai, L. Pedicone, H. Patino, and S. Durrant. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
24. van Burik, J.-A. H., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:e61-e65.
25. Walsh, T. J., I. Raad, T. F. Patterson, P. Chandrasekar, G. R. Donowitz, R. Graybill, R. E. Greene, R. Hachem, S. Hadley, R. Herbrecht, A. Langston, A. Louie, P. Ribaud, B. H. Segal, D. A. Stevens, J.-A. H. van Burik, C. S. White, G. Corcoran, J. Gogate, G. Krishna, L. Pedicone, C. Hardalo, and J. R. Perfect. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.